Abstract
Background: Hemolytic Uremic Syndrome (HUS) caused by infections with Shiga toxin (Stx)-producing E. coli is a life-threatening complication characterized by acute renal failure, thrombocytopenia and hemolytic anemia. Stx is the main pathogenic factor. Therefore, the mouse model by intravenous administration of a single lethal dose of Stx is often used to explore its pathogenic mechanisms.
Objective: The aim of this work was to develop an alternative mouse model of Stx type 2 (Stx2) intoxication to evaluate new therapeutic strategies.
Methods and Results: One lethal dose of Stx2 was divided in four daily doses. We observed a dose-dependent toxicity characterized by neutrophilia, leukocytopenia and renal damage. Most importantly, we demonstrated that the polyclonal anti-Stx2 serum was able to protect mice from fatal evolution even when administered together the third dose of Stx2.
Conclusion: This model would provide an advantage for evaluation of therapeutic strategies. Furthermore, the results presented herein suggest that appropriate treatment with anti-Stx2 agents following the appearance of initial clinical signs may block the ongoing outcome or may alleviate disease in patients who have just been diagnosed with HUS. However, the delay in the onset of therapy would be unsafe.
Keywords: Shiga toxin, mouse model, neutralizing antibodies, HUS, STEC, therapy.
Current Pharmaceutical Design
Title:Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS)
Volume: 22 Issue: 34
Author(s): Maria Pilar Mejias, Romina Jimena Fernandez-Brando, Maria Victoria Ramos, Maria Jimena Abrey-Recalde, Elsa Zotta, Roberto Meiss and Marina Sandra Palermo
Affiliation:
Keywords: Shiga toxin, mouse model, neutralizing antibodies, HUS, STEC, therapy.
Abstract: Background: Hemolytic Uremic Syndrome (HUS) caused by infections with Shiga toxin (Stx)-producing E. coli is a life-threatening complication characterized by acute renal failure, thrombocytopenia and hemolytic anemia. Stx is the main pathogenic factor. Therefore, the mouse model by intravenous administration of a single lethal dose of Stx is often used to explore its pathogenic mechanisms.
Objective: The aim of this work was to develop an alternative mouse model of Stx type 2 (Stx2) intoxication to evaluate new therapeutic strategies.
Methods and Results: One lethal dose of Stx2 was divided in four daily doses. We observed a dose-dependent toxicity characterized by neutrophilia, leukocytopenia and renal damage. Most importantly, we demonstrated that the polyclonal anti-Stx2 serum was able to protect mice from fatal evolution even when administered together the third dose of Stx2.
Conclusion: This model would provide an advantage for evaluation of therapeutic strategies. Furthermore, the results presented herein suggest that appropriate treatment with anti-Stx2 agents following the appearance of initial clinical signs may block the ongoing outcome or may alleviate disease in patients who have just been diagnosed with HUS. However, the delay in the onset of therapy would be unsafe.
Export Options
About this article
Cite this article as:
Mejias Pilar Maria, Fernandez-Brando Jimena Romina, Ramos Victoria Maria, Abrey-Recalde Jimena Maria, Zotta Elsa, Meiss Roberto and Palermo Sandra Marina, Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS), Current Pharmaceutical Design 2016; 22 (34) . https://dx.doi.org/10.2174/1381612822666160628080350
DOI https://dx.doi.org/10.2174/1381612822666160628080350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences
Current Neuropharmacology Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Hydatid Disease: Current Status of Chemotherapy and Drug Delivery Systems
Current Drug Therapy Nitrergic Response to Clostridium perfringens Infection in the Rat Brain Regions Effect of Red Light Irradiation
Central Nervous System Agents in Medicinal Chemistry Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Current Pharmaceutical Design A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery Potential Neuroprotective Effect of Cannabinoids in COVID-19 Patients
Current Topics in Medicinal Chemistry Progress in the Discovery of BACE Inhibitors
Current Pharmaceutical Design Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry A Review of Pharmacological and Phytochemical Studies on Convolvulaceae Species <i>Rivea</i> and <i>Ipomea</i>
Current Traditional Medicine Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery